Do men and women get different Yervoy (ipilimumab) side effects?
The information provided here does not include any sex-stratified safety results for Yervoy (ipilimumab), so it is not possible to say whether toxicity differs in males versus females based on these materials.
What safety data would show a male vs female toxicity difference?
To determine whether Yervoy toxicity differs by sex, researchers and regulators typically look for sex-specific rates of key adverse events (for example, immune-related events such as colitis, hepatitis, dermatitis, pneumonitis, and endocrinopathies), plus differences in:
- Overall adverse event frequency
- Rates of grade 3–4 events
- Discontinuation rates due to toxicity
- Treatment-related deaths (if reported)
- Time to onset by sex
Where to check this in real-world labeling or trials
The quickest way to answer this from primary materials is to look for a “sex” or “gender” subsection in Yervoy’s prescribing information or trial safety tables, usually under sections describing adverse reactions or clinical study safety. Those tables often report adverse events overall and sometimes by severity (grade) and system organ class, with a breakdown by demographic factors including sex.
If you share the source, I can answer precisely
If you paste the relevant Yervoy safety text/table (or a link/title of the document you’re using), I can extract whether the reported toxicity differs between males and females and summarize the specific adverse events where differences were seen.